The application of excess hazard models for plausible long-term extrapolation in cost-effectiveness: a re-evaluation of immunotherapy in advanced non-small cell lung cancer using the KEYNOTE-024 trial.
- DOI
- 10.1007/s10198-026-01981-w
- Published
- 2026 Aug 21
- Container
- The European journal of health economics : HEPAC : health economics in prevention and care
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s10198-026-01981-w,
title = {The application of excess hazard models for plausible long-term extrapolation in cost-effectiveness: a re-evaluation of immunotherapy in advanced non-small cell lung cancer using the KEYNOTE-024 trial.},
author = {Kim K and Sweeting M and Wilking N and Jönsson L},
year = {2026},
journal = {The European journal of health economics : HEPAC : health economics in prevention and care},
doi = {10.1007/s10198-026-01981-w},
url = {https://doi.org/10.1007/s10198-026-01981-w}
}RIS
TY - JOUR TI - The application of excess hazard models for plausible long-term extrapolation in cost-effectiveness: a re-evaluation of immunotherapy in advanced non-small cell lung cancer using the KEYNOTE-024 trial. AU - Kim K AU - Sweeting M AU - Wilking N AU - Jönsson L PY - 2026 JO - The European journal of health economics : HEPAC : health economics in prevention and care DO - 10.1007/s10198-026-01981-w UR - https://doi.org/10.1007/s10198-026-01981-w ER -
APA
K, K., M, S., N, W., & L, J. (2026). The application of excess hazard models for plausible long-term extrapolation in cost-effectiveness: a re-evaluation of immunotherapy in advanced non-small cell lung cancer using the KEYNOTE-024 trial.. The European journal of health economics : HEPAC : health economics in prevention and care. https://doi.org/10.1007/s10198-026-01981-w
Source records
- pubmed · retrieved 2026-09-26T21:48:05.238Z